Sleep quality in children with hepatic glycogen storage diseases, a prospective observational pilot study

Lucas Agnoletto1,2, Moya Vandeleur1,3, Mary White1,4,5

  • 1Murdoch Children's Research Institute Melbourne Victoria Australia.

JIMD Reports
|December 26, 2024
PubMed

Insights

Children with hepatic glycogen storage diseases (GSDs) experience poor sleep quality and reduced quality of life (QoL). Overnight feeding strategies, particularly bolus feeds, may negatively impact sleep more than glucose levels in managing GSDs.

Area of Science:

  • Pediatric Endocrinology
  • Sleep Medicine
  • Metabolic Disorders

Background:

  • Hepatic glycogen storage diseases (GSDs) involve enzyme defects in liver glycogen metabolism.
  • Carbohydrate supplementation is common to prevent overnight hypoglycemia in hepatic GSDs.
  • Emerging evidence suggests overnight dysglycemia may impact sleep quality in children with hepatic GSDs.

Purpose of the Study:

  • To report sleep quality and duration in children with hepatic GSDs.
  • To investigate the relationship between nocturnal glycemic profiles, dietary management, and sleep outcomes.
  • To assess quality of life (QoL) in this pediatric cohort.

Main Methods:

  • Prospective observational study over 7 days in 7 children (aged 1-17 years) with hepatic GSD.
  • Utilized actigraphy, sleep diaries, and questionnaires for objective and subjective sleep assessment.
  • Monitored nocturnal glycemic profiles using continuous glucose monitoring (CGM) and recorded dietary management strategies.

Main Results:

  • Objective and subjective sleep quality were poor; no child met recommended sleep duration.
  • Significant daytime sleepiness and poor sleep hygiene were reported.
  • Children on overnight bolus feeds (OBF) had shorter sleep duration compared to other strategies; QoL outcomes were poor.

Conclusions:

  • Children with hepatic GSDs commonly experience sleep disturbances and reduced QoL.
  • Overnight nutritional interventions, especially OBFs, may be more detrimental to sleep than glucose levels.
  • Future management strategies should consider the impact of overnight feeding on sleep and QoL.
Abstract

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.1K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
53